Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.
about
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.Analysis of Reverse Phase Protein Array Data: From Experimental Design towards Targeted Biomarker DiscoveryReverse Phase Protein Arrays-Quantitative Assessment of Multiple Biomarkers in Biopsies for Clinical UseHow may targeted proteomics complement genomic data in breast cancer?Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society.Reverse-phase protein microarray highlights HER2 signaling activation in immunohistochemistry/FISH/HER2-negative breast cancers.Variation in cell signaling protein expression may introduce sampling bias in primary epithelial ovarian cancerHost response during Yersinia pestis infection of human bronchial epithelial cells involves negative regulation of autophagy and suggests a modulation of survival-related and cellular growth pathways.HER-2 assessment in formalin-fixed paraffin-embedded breast cancer tissue by well-based reverse phase protein arrayFunctional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy.Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine.Recent progress in protein profiling of clinical tissues for next-generation molecular diagnostics.Evaluation of Protein Profiles From Treated Xenograft Tumor Models Identifies an Antibody Panel for Formalin-fixed and Paraffin-embedded (FFPE) Tissue Analysis by Reverse Phase Protein Arrays (RPPA)A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.Precision oncology based on omics data: The NCT Heidelberg experience.Reverse phase protein arrays: mapping the path towards personalized medicine.Multiple protein analysis of formalin-fixed and paraffin-embedded tissue samples with reverse phase protein arraysNeuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation.Phosphoprotein secretome of tumor cells as a source of candidates for breast cancer biomarkers in plasma.A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity.Implications of functional proteomics in breast cancer.Toward improving the proteomic analysis of formalin-fixed, paraffin-embedded tissue.What lies beneath: looking beyond tumor genetics shows the complexity of signaling networks underlying drug sensitivity.Application of molecular technologies for phosphoproteomic analysis of clinical samples.Proteomic analysis of tissue samples in translational breast cancer research.A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer.Subtyping of breast cancer using reverse phase protein arrays.HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.Using tissue samples for proteomic studies-critical considerations.Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.Deciphering the complexity of the cancer proteome for diagnostic applications.Reverse Phase Protein Microarrays.Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer.A reverse-phase protein microarray-based screen identifies host signaling dynamics upon Burkholderia spp. infection.Constitutive expression of microRNA-150 in mammary epithelium suppresses secretory activation and impairs de novo lipogenesis.Signaling pathway profiling using reverse-phase protein array and its clinical applications.Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients.Protein biomarkers for subtyping breast cancer and implications for future research.
P2860
Q27853216-3064D984-5AA2-4515-BC17-45121B921CB5Q28080766-F638BC04-3583-4911-9E59-AF907FDD4397Q28083256-76015EAD-7867-4E00-B70B-C0E2CAD4EAE7Q31140924-D2A8CB2F-1997-4199-B342-BF939AE8F54DQ33850616-FD5ABEAC-EA7C-4760-A0A1-E6BBE5EF83DAQ34777067-DF75209A-FC45-4C41-8733-78848FC3D429Q35035679-C936A44B-22C0-4103-8A52-382CB14C6968Q35082315-6224DC05-9FF0-4B68-997F-02E0AEAE825AQ35184966-DE76D946-08E2-491F-B725-39F37CFED2B8Q35328194-3B040625-2349-4F37-A5E5-B84EECD913C0Q35560129-1A7A1333-7D3D-49DE-BA2B-1FAD0E70D384Q35714211-10D7A629-221D-479F-AAC9-FDC59577CEC3Q36134032-04A50C57-3BFC-4A0F-8A81-18A6370D8BAEQ36186223-6A3C9E4E-A0A0-47E3-A18D-BF9A2B17DCC3Q36396606-D3C33BA1-AC10-4E9B-ACF2-595E518C619AQ36519831-4AF82A4B-95A8-449C-A929-8CD0166A166DQ37160952-FA777EA7-E919-474D-873E-6809DDD7DFC9Q37568043-17BFA1E8-076C-4E2F-BA1C-774FDE199380Q37687414-B2A891AA-44B4-4970-9D77-A261DE5AC7F0Q37694673-264C43C2-C50F-4AD7-89D1-B5BB2E6A75F9Q37698227-FCD1A5A4-763D-44CF-8EF9-390DAD6B550AQ38132919-A2660975-6740-453F-B9D6-9F9557ED8765Q38142730-D01F7CF2-04D7-4D10-9D6C-94856A4923A3Q38194417-123D60D9-CB3D-4796-9BFC-2EA9228F4217Q38212502-7B66E626-C8A2-4FFF-97A7-37506C76312BQ38248193-D94BF66E-FF76-42DC-942C-F5D11749BE6BQ38268585-018F47FA-949E-4B99-B0F3-BFE7A6302606Q38301236-C24D6378-0D52-45C4-8B2C-D15AADFED0BCQ38315127-66F54C13-88E6-4ECB-9BF7-464F197C68B6Q38623361-F2F0F5B8-E32D-44C9-B28A-37063E51E8B3Q38676337-B376C4A4-2770-4075-83E0-F85FF974279BQ38787411-41BA83DD-8D09-4F3E-9765-E4214E525C6EQ38818107-85419D9E-50EE-4EF0-BFC1-61BD05C4722AQ38963132-C8E819A6-D27B-4D4D-BD72-4D27ED1FC522Q38973213-8074E872-3D05-4C5C-95A2-DF38F704F2D0Q39301635-506B3B39-5BF2-4EA9-BCD6-B28633F83389Q39377837-74D1867E-D51C-4AA7-A840-74F1F939772AQ45058304-83B64B4D-E6F2-492D-A24E-E49C53C557B2Q47146356-35ADFE7A-267E-4878-A45B-8A0F1A5BA544Q47261659-45E8F1B4-599B-4D24-9EEE-E35E5F472A91
P2860
Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Molecular analysis of HER2 sig ...... in pathway activation mapping.
@ast
Molecular analysis of HER2 sig ...... in pathway activation mapping.
@en
Molecular analysis of HER2 sig ...... in pathway activation mapping.
@nl
type
label
Molecular analysis of HER2 sig ...... in pathway activation mapping.
@ast
Molecular analysis of HER2 sig ...... in pathway activation mapping.
@en
Molecular analysis of HER2 sig ...... in pathway activation mapping.
@nl
prefLabel
Molecular analysis of HER2 sig ...... in pathway activation mapping.
@ast
Molecular analysis of HER2 sig ...... in pathway activation mapping.
@en
Molecular analysis of HER2 sig ...... in pathway activation mapping.
@nl
P2093
P2860
P50
P1476
Molecular analysis of HER2 sig ...... in pathway activation mapping.
@en
P2093
Angela DeMichele
Axel Walch
Christine Waldhör
Claudia Wolff
Emanuel F Petricoin
Heinz Höfler
Holger Bronger
I-SPY 1 TRIAL Investigators
Ingrid Becker
Jianghong Deng
P2860
P304
P356
10.1158/1078-0432.CCR-12-0452
P407
P577
2012-10-08T00:00:00Z